Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

NCRI 2019 | Identifying the factors in gene regulatory networking in AML

Constanze Bonifer • 8 Nov 2019
NCRI 2019
Acute Myeloid Leukemia Leukemia

Constanze Bonifer, PhD, University of Birmingham, Birmingham, UK, continues on the subject of sub-type specific aberrant transcriptional programming in acute myeloid leukemia (AML). Recorded at the 2019 National Cancer Research Institute (NCRI) Annual Cancer Conference, in Glasgow, UK.
For more information about the NCRI Cancer Conference, visit https://conference.ncri.org.uk.

More from Constanze Bonifer

The impact of various chromosomal abnormalities observed in AML & insights into RUNX1-ETO 3:48
The impact of various chromosomal abnormalities observed in AML & insights into RUNX1-ETO
Constanze Bonifer • 16 Mar 2023
The impact of CEBPA mutations & insights into the gene regulatory network of CEBPA-double mutant AML 3:15
The impact of CEBPA mutations & insights into the gene regulatory network of CEBPA-double mutant AML
Constanze Bonifer • 16 Mar 2023
Using transcriptional network analysis to better understand AML development and evolution 4:09
Using transcriptional network analysis to better understand AML development and evolution
Constanze Bonifer • 16 Mar 2023
The molecular impact of RUNX1 mutations in AML 3:18
The molecular impact of RUNX1 mutations in AML
Constanze Bonifer • 16 Mar 2023

Related Videos

HARMONY Alliance study: validation of MRD as a surrogate endpoint in AML 8:00
HARMONY Alliance study: validation of MRD as a surrogate endpoint in AML
Jesse Tettero • 6 Dec 2025
POD36 as a prognostic marker and clinical tool in frontline CLL 3:03
POD36 as a prognostic marker and clinical tool in frontline CLL
Paul Hampel • 8 Dec 2025
AI‑driven virtual tumor board enhances precision care in AML: refining AI use in hematology 7:37
AI‑driven virtual tumor board enhances precision care in AML: refining AI use in hematology
David Swoboda • 5 Dec 2025
Recent advancements in the understanding of Richter’s transformation 1:00
Recent advancements in the understanding of Richter’s transformation
Elisa ten Hacken • 8 Dec 2025
The content of VJHemOnc is intended for healthcare professionals